🔥🐔 BizChicken 🐔🔥
Companies Similar to Intra-Cellular Therapies, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Athira Pharma, Inc.
ATH-1017
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.
Symbol: ATHA
Recent Price: $0.55
Industry: Biotechnology
CEO: Dr. Mark J. Litton M.B.A., Ph.D.
Sector: Healthcare
Employees: 65
Address: 18706 North Creek Parkway, Bothell, WA 98011
Phone: 425 620 8501
Last updated: 2024-12-31
Capricor Therapeutics, Inc.
CAP-1002
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.
About | Leadership | Directors | About | About | Contact | Careers | About | About | About | About
Symbol: CAPR
Recent Price: $13.76
Industry: Biotechnology
CEO: Dr. Linda Marbán Ph.D.
Sector: Healthcare
Employees: 101
Address: 10865 Road to the Cure, San Diego, CA 92121
Phone: 310 358 3200
Leadership
- Linda Marbán, Ph.D., Chief Executive Officer and Director
- Kristi A. H. Elliott, Ph.D., Chief Science Officer
- AJ Bergmann, M.B.A., Chief Financial Officer
- Karen G. Krasney, J.D., Executive Vice President and General Counsel
- Mark Awadalla, Vice President of Clinical Operations
- Jonathan Tayco, Vice President of Program Management and Business Operations
- Minghao Sun, Ph.D., Vice President of Research and Product Development
- Yushi Feng, Ph.D., Vice President of Regulatory Affairs
- Frank Litvack M.D., FACC, Executive Chairman
- Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
- Earl M. (Duke) Collier Jr., Director
- George W. Dunbar, Jr., Director
- Philip J. Gotwals, Ph.D., Director
- Michael Kelliher, Director
- David B. Musket, Director
- Karimah Es Sabar, Director
Last updated: 2024-12-31
Cyclerion Therapeutics, Inc.
CY6463
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.
Symbol: CYCN
Recent Price: $3.45
Industry: Biotechnology
CEO: Dr. Regina Graul Ph.D.
Sector: Healthcare
Employees: 1
Address: 245 First Street, Cambridge, MA 02142
Phone: 857 327 8778
Last updated: 2024-12-31
Inhibrx Biosciences, Inc.
Therapeutic Candidates (INBRX-109, INBRX-106)
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.
Symbol: INBX
Recent Price: $15.14
Industry: Biotechnology
CEO: Mr. Mark Paul Lappe
Sector: Healthcare
Employees: 166
Address: 11025 North Torrey Pines Road, La Jolla, CA 92037
Phone: 858-795-4220
Last updated: 2024-12-31
Pasithea Therapeutics Corp.
Therapies for CNS diseases
Pasithea Therapeutics Corp. is a biotechnology company engaged in research and discovery of treatments for psychiatric and neurological disorders. It plans to operate anti-depression clinics and provide business support services, using trained pharmacists to administer intravenous infusions of ketamine. Founded in 2020, the company is based in Miami Beach, Florida.
Symbol: KTTA
Recent Price: $2.95
Industry: Biotechnology
CEO: Dr. Tiago Reis Marques M.D., Ph.D.
Sector: Healthcare
Employees: 8
Address: 1111 Lincoln Road, Miami Beach, FL 33139
Phone: 702 514 4174
Last updated: 2024-12-31
PharmaCyte Biotech, Inc.
Cell-in-a-Box
Pharma Cyte Biotech, Inc. is a biotechnology company focused on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites. Their therapies are based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology, used for treating various cancers and diabetes.
About | Management | Directors | ESG | About | Directors | Contact | ESG | About | About | About | About
Symbol: PMCB
Recent Price: $1.55
Industry: Biotechnology
CEO: Mr. Joshua N. Silverman
Sector: Healthcare
Employees: 2
Address: 3960 Howard Hughes Parkway, Las Vegas, NV 89169
Phone: 917 595 2850
Leadership
- Joshua N. Silverman, Independent Director
- Dr. Michael M. Abecassis, Independent Director
- Robert Weinstein, Director
- Wayne R. Walker, Director
- Jonathan L. Schechter, Independent Director
- Dr. Abecassis, Director
- Kenneth L. Waggoner, Independent Director
- Daniel C. Farb, Independent Director
- Daniel C. Allen, Independent Director
- Jack E. Stover, Independent Director
Last updated: 2024-12-31
Alto Neuroscience, Inc.
ALTO-100, ALTO-300, ALTO-101, ALTO-203, ALTO-202
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in psychiatry drug development, with a range of innovative treatments targeting major depressive disorder and cognitive impairments.
Symbol: ANRO
Recent Price: $4.20
Industry: Biotechnology
CEO: Dr. Amit Etkin M.D., Ph.D.
Sector: Healthcare
Employees: 78
Address: 369 South San Antonio Road, Los Altos, CA 94022
Phone: (650) 200-0412
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
ACADIA Pharmaceuticals Inc.
NUPLAZID
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of small molecule drugs to treat unmet medical needs in central nervous system disorders. Key products and developments include NUPLAZID for Parkinson's disease-related psychosis and a diverse pipeline addressing Alzheimer's disease, schizophrenia, Rett syndrome, and pain management.
Symbol: ACAD
Recent Price: $16.69
Industry: Biotechnology
CEO: Ms. Catherine E. Owen Adams
Sector: Healthcare
Employees: 597
Address: 12830 El Camino Real, San Diego, CA 92130
Phone: 858 558 2871
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Celularity Inc.
CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.
About | Leadership | Directors | About | About | About | About | Directors | Careers | About | About | About | About | About | About
Symbol: CELU
Recent Price: $2.05
Industry: Biotechnology
CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
Sector: Healthcare
Employees: 120
Address: 170 Park Avenue, Florham Park, NJ 07932
Phone: 908 768 2170
Leadership
- Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
- David Beers, CFA, Chief Financial Officer
- Stephen Brigido, DPM, President, Degenerative Diseases
- John Haines, Global Manager and Chief Administrative Officer
- K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
- John Colerangle, DVM, Ph.D., Regulatory Affairs
- Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
- Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
- Carmine Palummo, Corporate Operations
- Tim Wilk, Technical Operations
- Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
- Peter Diamandis, M.D., Director
- Dean Kehler, Director
- Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
- Diane Parks, Director
Last updated: 2024-12-31
Cognition Therapeutics, Inc.
CT1812
Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.
Symbol: CGTX
Recent Price: $0.75
Industry: Biotechnology
CEO: Ms. Lisa Ricciardi
Sector: Healthcare
Employees: 25
Address: 2500 Westchester Avenue, Purchase, NY 10577
Phone: 412 481 2210
Leadership
- Lisa Ricciardi, Chief Executive Officer
- Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
- John Doyle, Chief Financial Officer
- Anita Cornet, Head of Quality
- Theresa Devins, DrPH, Vice President, Clinical Operations
- Mary Hamby, Ph.D., Vice President, Research
- Bobby Horn, Corporate Controller
- Jennifer Iaci, Vice President, Development Operations
- Steven A. Weissman, Ph.D., Vice President and Head of CMC
- Jack A. Khattar, CEO
- Aaron Fletcher, Ph.D.,
- Brett P. Monia, Ph.D., CEO
- Ellen B. Richstone,
- Peggy Wallace,
Last updated: 2024-12-31
Cingulate Inc.
CTx-1301
Cingulate Inc. is focused on developing product candidates for treating attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. Its pipeline includes CTx-1301 and CTx-1302 for ADHD, and CTx-2103 for anxiety.
About | Management | Directors | About | About | Contact | Contact | Careers | About | About | About
Symbol: CING
Recent Price: $4.98
Industry: Biotechnology
CEO: Dr. Shane J. Schaffer Pharm.D.
Sector: Healthcare
Employees: 13
Address: 1901 West 47th Place, Kansas City, KS 66205
Phone: 913 942 2300
Leadership
- Shane J. Schaffer, PharmD, Chairman, Chief Executive Officer
- Peter J. Werth, Director
- Jeff Ervin, Director
- Bryan Lawrence, Director
- Jay Roberts, Director
Last updated: 2024-12-31
Cyclo Therapeutics, Inc.
Trappsol Cyclo
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company focused on developing cyclodextrin-based products for various diseases, with its lead drug candidate Trappsol Cyclo undergoing Phase III trials for Niemann-Pick Type C disease and exploration for Alzheimer's treatment.
Contact | Contact | News | About | About | About | About | About | About | About | About | About | Careers | About | About | About
Symbol: CYTH
Recent Price: $0.60
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mr. N. Scott Fine
Sector: Healthcare
Employees: 8
Address: 6714 NW 16th Street, Gainesville, FL 32653
Phone: 386 418 8060
Last updated: 2024-12-31
Inhibikase Therapeutics, Inc.
Ik T-148009
Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.
About | Leadership | Directors | About | About | About | Contact | Careers | About | About | About | About
Symbol: IKT
Recent Price: $3.24
Industry: Biotechnology
CEO: Dr. Milton H. Werner Ph.D.
Sector: Healthcare
Employees: 8
Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339
Phone: 678 392 3419
Leadership
- Milton H. Werner, Ph.D., President and CEO
- C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
- Garth Lees-Rolfe, CPA, Chief Financial Officer
- Dan Williams, Controller
- Terence Kelly, Ph.D., Medicinal Chemistry Consultant
- Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
- Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
- Roberto Bellini, Managing Partner at BSQUARED Capital
- Dennis Berman, Serial Entrepreneur
- David Canner, Ph.D., Partner at Soleus Capital
- Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
- Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
- Amit Munshi, Chief Executive Officer of Orna Therapeutics
Last updated: 2024-12-31
Indaptus Therapeutics, Inc.
Decoy20
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.
Symbol: INDP
Recent Price: $0.87
Industry: Biotechnology
CEO: Mr. Jeffrey A. Meckler
Sector: Healthcare
Employees: 7
Address: 3 Columbus Circle, New York, NY 10019
Phone: 347 480 9760
Last updated: 2024-12-31
Intra-Cellular Therapies, Inc.
CAPLYTA
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.
About | About | Leadership | Directors | Sustainability | Contact | Careers | Careers | About | News | About | Careers
Symbol: ITCI
Recent Price: $83.48
Industry: Drug Manufacturers - Specialty & Generic
CEO: Dr. Sharon Mates Ph.D.
Sector: Healthcare
Employees: 610
Address: 430 East 29th Street, New York, NY 10016
Phone: 646 440 9333
Leadership
- Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
- Michael I. Halstead, J.D., President
- Mark Neumann, Executive Vice President, Chief Commercial Officer
- Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
- Sanjeev Narula, Executive Vice President, Chief Financial Officer
- John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
- Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
- Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
- Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
- Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
- Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
- Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
- Rory B. Riggs, MBA, Co-Founder and Director
- E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
- Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals
Last updated: 2024-12-31
iTeos Therapeutics, Inc.
inupadenant, EOS-448
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.
About | Leadership | Directors | About | About | About | About | Contact | Careers | About | About | About | About | About | About
Symbol: ITOS
Recent Price: $7.29
Industry: Biotechnology
CEO: Dr. Michel Detheux Ph.D.
Sector: Healthcare
Employees: 157
Address: 321 Arsenal Street, Cambridge, MA 02472-5710
Phone: 339 217 0161
Leadership
- Michel DETHEUX, President, Chief Executive Officer
- Matt CALL, Chief Operating Officer
- Matthew GALL, Chief Financial Officer
- Yvonne MCGRATH, Chief Scientific Officer
- David Feltquate, Chief Medical Officer
- Philippe BRANTEGEM, Executive Vice President of Human Resources
- Adi OSOVSKY, Executive Vice President of Legal
- David HALLAL, Chair of the Board
- Aaron DAVIS,
- Jill DESIMONE,
- David LEE,
- Tim VAN HAUWERMEIREN,
- Tony HO,
- Robert IANNONE,
- Ann RHOADS,
Last updated: 2024-12-31
Intellia Therapeutics, Inc.
NTLA-2001, NTLA-2002, NTLA-5001
Intellia Therapeutics, Inc. is a genome editing company specializing in developing therapeutics, with a focus on in vivo and ex vivo programs, including treatments for transthyretin amyloidosis, hereditary angioedema, and acute myeloid leukemia. The company also develops engineered cell therapies and offers CRISPR/Cas9 tools.
News | About | About | Contact | Careers | Culture | DEI | Careers | Careers | Careers | Culture | Jobs | Jobs | Careers | Careers | Careers | Jobs | About | About | About
Symbol: NTLA
Recent Price: $11.41
Industry: Biotechnology
CEO: Dr. John M. Leonard M.D.
Sector: Healthcare
Employees: 526
Address: 40 Erie Street, Cambridge, MA 02139
Phone: 857 285 6200
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31